Stock NPS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases NPS Pharmaceuticals, Inc.

Equities

US62936P1030

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for NPS Pharmaceuticals, Inc.
2015 NPS Pharmaceuticals : Shire confident on 2015 after NPS deal, binge-eating drug approval RE
2015 NPS Pharmaceuticals : Shire shares jump as drug approval vindicates $5.2 billion NPS purchase RE

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NPS Pharmaceuticals : Shire Completes Acquisition of NPS Pharma
PR
NPS Pharmaceuticals : Biotech Stocks Review - Arena Pharma, Amgen, NPS Pharma, ZIOPHARM Oncology, and Advaxis
PR
NPS Pharmaceuticals : FDA Approves Natpara® (parathyroid hormone) for Injection as an Adjunct to Calcium and Vitamin D to Control Hypocalcemia in Patients with Hypoparathyroidism
BU
NPS Pharmaceuticals : Ryan & Maniskas, LLP : Announces Investigation of NPS Pharmaceuticals, Inc.
PR
NPS Pharmaceuticals : Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of NPS Pharmaceuticals, Inc. Stockholders
BU
NPS Pharmaceuticals : PLShire to Acquire NPS Pharma as Further Step in Building a Leading Biotech
PR
NPS Pharmaceuticals : Pharma to Present at J.P. Morgan Healthcare Conference
BU
NPS Pharmaceuticals : Pharma to Present at Oppenheimer Healthcare Conference
BU
NPS Pharmaceuticals : European Medicines Agency Validates Marketing Authorization Application for Natpar® (parathyroid hormone (rDNA)) in Hypoparathyroidism
BU
NPS Pharmaceuticals : Pharma to Present at Deutsche Bank BioFEST Conference
BU
NPS Pharmaceuticals : Teduglutide Granted Orphan Drug Designation in Japan
BU
NPS Pharmaceuticals : Pharma to Present at Jefferies Global Healthcare Conference
BU
NPS Pharmaceuticals : Pharma Reports Third-Quarter 2014 Financial Results
BU
NPS Pharmaceuticals : Pharma Appoints Pierre Legault to Board of Directors
BU
NPS Pharmaceuticals : Pharma to Report Third Quarter 2014 Financial Results
BU
NPS Pharmaceuticals : PDUFA Action Date for Natpara® BLA Extended Three Months to January 24, 2015
BU
NPS Pharmaceuticals : Pharma : to Present at Leerink Partners Rare Disease Roundtable
BU
NPS Pharmaceuticals : New Product Launch, Accelerated Drug Approvals, Study Initiation, and Market Activity - Research Reports on Johnson & Johnson, Merck, Medtronic, Pharmacyclics and NPS Pharma
PR
NPS Pharmaceuticals : FDA Advisory Committee Recommends Approval of Natpara® for Long-Term Treatment of Hypoparathyroidism
BU
NPS Pharmaceuticals : Pharma Stock Trading Halted Today; FDA Advisory Committee to Review Natpara® Biologics License Application
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News NPS Pharmaceuticals, Inc.
  5. Press Releases